New Diabetes Products

Hybrid Closed Loop System.

NEW! The Suspend before low§ option avoids lows and rebound highs proactively by automatically stopping insulin 30 minutes before you reach your pre-selected low limits, then automatically restarts insulin when your levels recover, all without bothersome alerts. NEW! The Auto Mode‡ option automatically adjusts your basal insulin delivery every 5 minutes based on your sugar levels to keep you in target range, all day and night. Watch Video View Brochure Get Started NEW! Guardian® Sensor 3 continuous glucose monitoring sensor. Introducing the most accurate sensor from Medtronic, now with up to 7 day wear and easy insertion. It is the FIRST and ONLY continuous glucose monitoring sensor FDA approved and trusted to control insulin dosing. Exclusive CONTOUR®NEXT LINK 2.4 meter1 Get easy and accurate CGM calibration, insulin dosing and remote bolusing with our exclusive meter. “This device will mean peace of mind, in knowing a person will be in normal blood sugar range a great majority of the time,” “It’s a medical device with the potential to change the lives of more than 1 million Americans who suffer from Type 1 diabetes.” KEEP YOUR GLUCOSE IN RANGE SMARTGUARD® HCL TECHNOLOGY. Quick and easy access to your glucose and insulin information, all from the home screen. Bright color screen for easy readability - day or night. Waterproof - so you can enjoy underwater activities. Quick and easy bolus from your meter. Fewer shots than multiple daily injections. The only sensor FDA approved and trusted to control insulin dosing. Easy to insert. Know at all times where your glucose levels are trending. Click here for assistance if your insurance does not currently cover the MiniMed 670G system. * Mean Absolute Relative Difference. ** 3-4 calibrations per day required. Continue reading >>

7 Diabetes Technology Updates For 2018

As I gathered my notes and thoughts about the potential of diabetes technology in 2018, I kept coming back to the running list of caveats and elephants in the room. Access and affordability have been headline-generating conversations across the diabetes community this year. On one hand, it feels a little weird to talk about crazy-advanced technology that will hopefully make its way to the diabetes community next year while we’re still trying to figure out why live-sustaining medication costs as much as it does. If you are struggling to afford insulin, do you have room to get excited about automated insulin delivery? But, innovation is important. The clinical trials and resources spent developing better, smarter, faster tools are essential to the grander conversation about improving the lives of people with diabetes. This shouldn’t ignore the Very Real issues that are being discussed, so I’m going to propose we try to walk and chew gum at the same time. Yes, I want better technology to help manage my diabetes. Yes, it should be affordable so that no one is priced out of quality diabetes care. When I think about the scope and potential of diabetes technology, it’s more than just a specific product or products that may come to market. So here’s a glimpse at some of the companies and movements that I am going to pay close attention to next year as diabetes technology looks to take another major step forward in 2018. Tandem’s PLGS Algorithm PLGS, or Predictive Low Glucose Suspend, Tandem’s algorithm that will predict and prevent hypoglycemia events is coming next year. That’s a fact. What I’m curious to see is what’s next. Operating in the world of upgradeable firmware (instead of just hardware) is a bit of a new journey for consumer health technology. Wh Continue reading >>

Fda Issues New Warning For 5 Diabetes Drugs

FDA Issues New Warning for 5 Diabetes Drugs Saxagliptin and alogliptin may increase the risk of heart failure The Food and Drug Administration (FDA) has reported that type 2 diabetes medications containing saxagliptin and alogliptin may increase the risk of heart failure especially in patients who already have cardiovascular or renal disease. The FDA is adding new warnings to the affected drug labels about this new safety risk. Saxagliptin and alogliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors that are indicated for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.In 2015, approximately 386,000 patients received a dispensed prescription for saxagliptin-containing products (saxagliptin and saxagliptin-metformin), and 56,000 patients received a dispensed prescription for alogliptin-containing products (alogliptin, alogliptin-pioglitazone, and alogliptin-metformin) from the U.S. outpatient retail pharmacy setting.The drugs impacted by this safety communication include: Oseni (alogliptin/pioglitazone; Takeda ) The FDA reviewed two large trials conducted in patients with heart disease. Findings from each trial revealed that more patients who received saxagliptin- or alogliptin-containing drugs were hospitalized for heart failure vs. patients who received placebo. In one of the trials, SAVOR, 3.5% of patients who received saxagliptin were hospitalized for heart failure vs. 2.8% in the placebo group. In the second trial, EXAMINE, 3.9% of patients treated with alogliptin were hospitalized for heart failure vs. 3.3% in the placebo group. Risk factors for hospitalization heart failure include a history of heart failure or renal impairment. RELATED:Impact of T2DM Meds on Heart Failure Hospitalization Explored Healthcare professionals should con Continue reading >>

Novo Nordisk Launches Two New Diabetes Drugs In U.s.

Novo Nordisk launches two new diabetes drugs in U.S. Novo Nordisk (NYSE: NVO ) today launched two new diabetes medications in pharmacies across the U.S. The Danish companys Ozempic product is a once-weekly GLP-1 receptor agonist designed to boost glycemic control in adults with Type II diabetes. The injection, administered in a pre-filled pen, won FDA approval in December . Fiasp, a fast-acting mealtime insulin, is indicated for adults with Type I and Type II diabetes. The FDA gave the insulin aspart injection the go-ahead in September last year. With 1.5 million new patients diagnosed with diabetes each year,we must continue to innovate and bring to market new options to meet the diverse needs of patients,David Moore, SVP of Novo Nordisks commercial business unit, said in prepared remarks. There is no one-size-fits-all approach to effectively managing diabetes and we are proud to add Ozempicand Fiasp to our market-leadingportfolio to give patients new treatment options. Our robust portfolio of diabetes products addresses the concerns and needs of people with diabetes, particularly around dosing and administration. Earlier this month, Novo Nordisk shares fell after the insulin-maker missed expectations on Wall Street with its fourth quarter and full-year financial results. The company posted profits of $1.38 billion on sales of $4.68 billion for the 3 months ended Dec. 31, for bottom-line loss of -5% on sales loss of -5% compared with the same period last year. Adjusted to exclude 1-time items, earnings per share were 57, behind consensus on The Street, where analysts were looking for sales of $4.86 billion. The company also noted that its boards chairman, Goran Ando, has decided not to seek re-election this year and that Helge Lund, a current member of the board, is s Continue reading >>

Technologies For Diabetes Management 2017-2027: Forecasts, Players, Opportunities

Glucose sensors, ketone sensors, insulin pens and pumps This report from IDTechEx covers mature, growing and emerging fields in diabetes technology, researched through primary interviews with companies, physicians and diabetic individuals to establish how the technological roadmap for diabetes management will develop over the next decade. Historically glucose levels have been monitored using disposable biosensors, whereby a drop of blood is placed on to a sensor and an associated reader provides the result. While the glucose test strip industry produces billions of single use sensors a year, cuts to medical budgets are driving profitability down. Current invasive methods of glucose monitoring result in low patient compliance, leading to poor glucose control and the associated long term health implications. These factors have led both start-ups and established players in the field to develop novel glucose sensing platforms based on alternative sampling sites and detection methods. Whilst many of these technologies will not be able to precisely replicate the accuracy of blood glucose measurements, some are making progress towards this goal and are achieving regulatory approval to commercialise products in to this emerging market. Advancements in diabetes care are not limited to glucose monitoring, novel insulin delivery platforms provide another area of growth for the industry, with wearable insulin pumps now widely available. Such devices contain a range of sensors to that enable the safe and controlled delivery of insulin to a patient. Progression in both glucose monitoring and insulin delivery technologies are enabling the delivery of a previously conceptual artificial pancreas system, able to deliver controlled insulin doses, based on sensor outputs to optimise glucos Continue reading >>

New Diabetes Treatment Tops Cleveland Clinic's Top 10 Medical Innovations 2018 List (photos)

CLEVELAND, Ohio -- An insulin pump that functions like an artificial pancreas ranked No. 1 on Cleveland Clinic's list of the Top 10 Medical Innovations for 2018. The announcement of the entire list will be made Wednesday as part of the Cleveland Clinic Medical Innovation Summit. Other innovations being honored include gene therapy for blindness, new ways of creating vaccines and targeted breast cancer treatment. The insulin pump, which will help patients with Type 1 diabetes, was judged to be the innovation that will have the biggest impact on healthcare next year. "This is a major breakthrough," said Dr. James Young, chairman of the Endocrinology and Metabolism Institute at the Cleveland Clinic. The pump senses blood glucose levels and delivers insulin via subcutaneous sensors, Young said. This year, a 20-person committee looked at more than 300 nominated innovations to find ones that are likely to have the biggest immediate impact, said the Clinic's Dr. Michael Roizen, who will host a multi-media presentation of the Top 10 Medical Innovations. Roizen is chairman of the Cleveland Clinic Wellness Institute and chief wellness officer. Roizen is excited about the rapid development of new vaccines, and the development of new ways to deliver them, an innovation that earned a spot on the list. "It means really radical changes in vaccine prevention," Roizen said. The presentation of the Top 10 Medical Innovations comes on the final day of the Medical Innovation Summit, which started Monday at the Huntington Convention Center. Below, the Top 10 Medical Innovations of 2018 are listed in order of importance: No. 1: Hybrid Closed-Loop Insulin Delivery System Hailed as the world's first artificial pancreas, the hybrid closed-loop insulin delivery system allows a glucose monitoring Continue reading >>

New Diabetes Tech On The Horizon: What’s Coming By Mid-2017 In The Us?

By Lynn Kennedy, Ava Runge, and Adam Brown What Abbott, Dexcom, LifeScan, Medtronic, Tandem, and others are bringing to make diabetes easier and less burdensome Want more news just like this? We’re living in the most exciting time ever in diabetes technology, and a slew of soon-to-launch products are going to subtract hassle from living with diabetes – fewer injections and fingersticks, less math, less data overload, less pain, and less worry. Equally important, most emerging technology shows excellent potential to improve glucose outcomes that matter, among them hypoglycemia, time-in-range, hyperglycemia, and A1c. Curious what’s coming? Read on for a summary of the insulin delivery and glucose monitoring devices expected to launch in the US by mid-2017 or earlier, based on the most recent company timelines (listed chronologically). This list is not fully comprehensive, but does cover the major device launches expected. A more detailed description of each device follows further below. New Insulin Delivery Devices Tandem’s t:slim X2 Insulin Pump – October-December 2016. The latest Tandem pump will add a new Bluetooth radio and enable software updates to add future Dexcom G5 connectivity and automated insulin delivery algorithms. Medtronic MiniMed Pro Infusion Set with BD FlowSmart technology – around late 2016. The long-awaited infusion set has several key improvements, most notably a new catheter that allows insulin to flow out of two holes (less occlusions). LifeScan’s OneTouch Via – early 2017. The bolus-only, super slim wearable device holds 200 units of insulin and can be worn for three days. Squeezing two buttons (including through clothes) – will discreetly deliver a two-unit bolus. Medtronic’s MiniMed 670G/Enlite 3 Hybrid Closed Loop – by Ap Continue reading >>

U.s. Diabetes Patients Are About To Get Some High-tech Relief

User-friendly devices to replace old, ‘barbaric’ tools ‘This is a crossroads for diabetes technology:’ analyst Diabetes devices may be having their iPhone moment. For decades, the daily routine of diabetics involved painful needles, finger-pricking lancets and imprecise glucose meters. Now, manufacturers have begun incorporating the slick and consumer-friendly designs of Silicon Valley, linking to phones and other tech devices. “This is a crossroads for diabetes technology,’’ said Raj Denhoy, an analyst at Jefferies in New York. September marked a breakthrough in the U.S., as regulators approved the first glucose-monitoring system that doesn’t need a blood sample, the FreeStyle Libre by Abbott Laboratories. The new devices do away with fingerpricks, changing an unpleasant, several-times-a-day routine into quiet monitoring in the background through a sensor worn on the back of the upper arm. Other companies have been left behind. Johnson & Johnson is closing its insulin-pump unit after failing to keep up with Medtronic Plc. DexCom Inc., the current leader in glucose-monitoring systems, lost a third of its market value on Sept. 28 after Abbott’s Libre got approval. On DexCom’s earnings conference call Wednesday executives, peppered with questions about the Libre, said the company hopes to introduce its own fingerprick-free device before the end of 2018. The comments about next-generation monitors helped assuage investors’ concerns about DexCom’s prospects, sending the stock up 9.5 percent in the two trading days following the results. “Companies who succeed will be those who can figure out this convergence of health care and technology,” said Arda Ural, a partner at Ernst & Young LLP in New York. “And they’re very different animals to bring Continue reading >>

Abbott Wins Fda Approval For Diabetes Device That Doesn't Require Routine Finger Pricks

The U.S. Food and Drug Administration approved Abbott’s FreeStyle Libre Flash Glucose Monitoring System for adults, which already is sold in 41 other countries. Abbott Laboratories has gained clearance to start selling in the U.S. the first continuous glucose monitor that does not require people with diabetes to routinely prick their fingers. The U.S. Food and Drug Administration on Wednesday approved Abbott’s FreeStyle Libre Flash Glucose Monitoring System for adults, which already is sold in 41 other countries. The device consists of a small sensor, about the size of a quarter, that’s worn on the back of the upper arm to continuously track glucose levels. The sensor, unlike other wearable sensors, does not require patients to prick their fingers for calibration. Patients can place a hand-held reader near the device to see their current glucose levels, trends, patterns and where those levels might be headed. They can then use those readings to figure out how much insulin to take to manage their diabetes. The device has not yet been approved for use by children in the U.S. but Abbott hopes to gain approval from the FDA. The company is not disclosing pricing information until it gets closer to launching the product in the U.S., which will likely be before the end of the year, said Abbott spokeswoman Vicky Assardo. But she said in an email the price will be “very similar” to the price in Europe, where the reader costs about $69, and each sensor, which lasts about 14 days, also costs about $69, before insurance. In the U.S., the sensor will last about 10 days. “We intentionally designed the product to make it as affordable as possible,” said Jared Watkin, Abbott senior vice president of diabetes care. In the U.S., continuous glucose monitors are often covered Continue reading >>

New Diabetes Technology To Expect In 2018

We're sorry, an error occurred. We are unable to collect your feedback at this time. However, your feedback is important to us. Please try again later. The start of a new year always brings curiosity about what's on tap in new diabetes technology, and we're excited to take an inside look, especially with the big JP Morgan Healthcare and Consumer Electronics Show events underway this month. Of course, these days Amazon and Google generate quite the medtech buzz, not to mention wearable smartwatches and Apple talk and the very many mobile health apps being developed . Some of the recent buzz includes FitBit investing $6M to develop a continuous glucose sensor, and rumors that Apple's developing its own super-secret continuous monitor built directly into its Apple Watch. On the flip side, you can't talk about innovation or D-tech these days without the lockstep concerns of access and affordability. It's encouraging to see reimbursement being more of a focus at the R&D stage of new products, and the latest news of Medicare coverage for the tubeless OmniPod pump and new Abbott FreeStyle Libre flash glucose monitor are big moves forward. We've reached out to many leading diabetes vendors and combed through public reports from investor earnings calls and other news announcements to compile this (not exhaustive) look at what's ahead in D-tech for this coming year. You might refer to this as Artificial Pancreas systems , but whatever the name it's about "closing the loop" in glucose-monitoring and insulin dosing. While we won't see any fully closed loops (requiring no user intervention) on the market during 2018, we'll certainly see progress from numerous players. Beta Bionics: This B-Corp startup in Boston now has its fourth-generation prototype of its iLet4 system, a dual-hor Continue reading >>

Apple Is Reportedly Working On Sensors For Diabetes Treatment

Apple is quietly developing sensors that can track the body’s blood sugar levels in a bid to help people with diabetes, CNBC reports. The company has apparently hired a small team of biomechanical engineers to work on the project, which would monitor glucose levels through contact with the skin, rather than through invasive blood tests or similar mechanisms. The company is basing the team working on the sensors out of an office in Palo Alto, rather than at its main headquarters. The engineers have apparently been working on the sensor technology for at least five years, and it is complete enough that Apple has started feasibility trials at clinical locations in the Bay Area. The company has also hired consultants that are helping it navigate complex health regulations, CNBC says. The team is reportedly managed by Johny Srouji, Apple's senior vice president of hardware technologies, but previously reported to Michael D. Hillman before he left the company in 2015. CNBC says the team is made up of about 30 people, including biomedical experts Apple hired away from major firms like Masimo Corp, Sano, Medtronic, and C8 Medisensors. Those hires, reported early last year, sparked speculation that Apple may indeed be working on such a product. The idea of wearable devices being used to manage conditions like diabetes was developed during Steve Jobs’ tenure as Apple head, but developing technology that can accurately measure blood sugar levels without piercing the skin is particularly difficult. John L. Smith, a biomedical expert who has published papers on the failure of non-invasive glucose sensors, said it was "the most difficult technical challenge I have encountered in my career." Apple’s in-development solution reportedly shines light through the skin to check curren Continue reading >>

2018 New Insulin Pump Comparisons And Reviews

Insulin pumps are NOT commodities. There are differences between systems (some subtle, some obvious) that make certain pumps better options for certain individuals. It is astounding that so many people are given little to no choice when it comes to selecting an insulin pump. Given that pump warranties last longer than the average marriage, it makes sense to invest some time in comparing the various devices before making a selection. Every member of our clinical team has personal and professional experience with every make and model of insulin pump. We are not employed by any pump company, and we are not easily pressured (although really good chocolate has been known to sway our opinion a bit), so we can offer you fair and impartial information/insight. Please use our pump comparisons to help make an educated decision. We have listed the positive and negative features that are unique to each pump. Features that are common to all pumps, such as allowing for multiple basal patterns, are not included. At the end of the day, the choice is yours. If you would like some expert input, feel free to contact our office and schedule some time to meet or speak with one of our clinicians. And for assistance applying your pump to achieve the best possible glucose management, please reach out. Continue reading >>

These Developments In Diabetes Care Will Shape The Industry Next Year

How Medtronic's MiniMed 670G grows Production delays hobbled the June launch of Medtronic's hybrid closed-loop system. The technology has been hailed as a milestone because it's the first insulin pump that delivers insulin somewhat automatically. The system combines a continuous glucose monitor, an algorithm and a pump. They work together to measure and analyze glucose levels to adjust the amount of insulin delivered accordingly. Medtronic's system is considered a hybrid closed-loop because although the Guardian Sensor 3 and MiniMed 670G pump work together, they still require some patient input. For example, patients need to enter information about what they're eating and calibrate their pumps using fingerstick testing. The Food and Drug Administration approved the system in September 2016, months earlier than expected. Medtronic had recently introduced the MiniMed 630G system, meaning a number of patients had just purchased a new device. The number of people wanting the new system caused a spike in demand that slowed production, creating a backlog of people waiting to buy it. The slowdown weighed on Medtronic's total diabetes segment, which accounts for about 7 percent of its total revenue. The category declined 2 percent in constant currency last quarter. It rose 4 percent last fiscal year, which ended in April. The company does not break out the total diabetes segment revenue by category, but intensive insulin management represents the bulk of its sales. That group declined low single digits last quarter. Last fiscal year, it grew high single digits. Medtronic expects to ramp up production in its fourth quarter, which ends in April. Analysts expect fixing the slowdown will help the diabetes segment grow again. Impact of Abbott's FreeStyle Libre Abbott launched its Fr Continue reading >>

Home - One Drop: Diabetes Management Made Simple

One Drop: Diabetes Management Made Simple Get everything you need, all in one place. One Drop | Mobile empowers you to track and analyze all your diabetes data glucose, medications, food, and activity with just one app. Set goals, track progress, and see results! One Drop | Chrome is a Bluetooth blood glucose monitor that syncs with the One Drop | Mobile app. Get all the test strips you need with a One Drop | Premium or One Drop | Plus subscription. One Drop | Experts is a personal diabetes coaching program designed to help you reach all your health goals. Work with a CDE available 24/7 to get the support you need in real-time. Track all the essentials Blood Glucose, Food, Meds and Activity all in one place. Wirelessly transmit blood glucose data via Bluetooth to the One Drop Mobile app. Get all the test strips you need with a One Drop | Premium or One Drop | Plus subscription. Work one-on-one with your One Drop | Expert, a personal diabetes coach available 24/7 to guide you, support you, and celebrate your accomplishments. One Drop | Experts has been Recognized by the American Diabetes Association for Quality Self-Management Education* and Support. Beautiful visual interface and clear reports that the app can generate for my healthcare provider. Best of all is the news feed articles and community stream where you can see how other users are managing diabetes. Smallest drop of blood! No more entering numbers in my phone! I love it all! This is the app that gets it... Bluetooth blood glucose tracking works perfectly. Medication reminder and tracker in one. . . There is even someone who chats with you and checks up on you. Finally a meter and strips I can afford. Experts are great too.... overall I love it and am totally happy with it!!! Get One Drop | Mobile for free on Continue reading >>

Focus: Diabetes Treatment

Diabetes incidence is growing around the globe; by 2030, one in every ten people is projected to have diabetes. Diabetes is a growing global epidemic. An estimated 387 million people in the world have diabetes, and the numbers are rising at an alarming speed. Managing this disease requires individually tailored patient plans involving improved lifestyle, diabetes education, balancing nutrition with physical activity and often medication. Even with the disease management tools available today, about 50 percent of people don't have their blood sugar at doctor-recommended levels. The central defect of diabetes is high levels of blood glucose. Blood glucose levels are the result of orchestrated actions by a number of hormones including insulin, incretins and glucagon among others, and organs including the pancreas, liver, kidneys, and muscle and fat tissue. For years, research and treatments have targeted primarily the pancreas, which produces the insulin needed to balance glucose levels in the blood. Janssen focuses on truly transformational therapies within the diabetes space and as the kidneys emerged as a potential target in the treatment of type 2 diabetes because of their role in filtering blood glucose Janssen followed the science and built an aggressive development plan. As such, Janssen launched the first SGLT2 inhibitor in the United States and it has been approved in over 60 countries around the world. However, with the burden of disease so high, we are not content with just this addition to the diabetes treatment paradigm. We continue to pursue novel mechanisms and treatments that will ultimately eliminate the disease. Janssen is proud to be part of the long Johnson & Johnson legacy in diabetes. You can view our full list of products, including our latest diabe Continue reading >>